Low Dose Lithium

Conclusion: Although it is yet to be determined which is more effective between lithium or lecanemab or donanemab, lithium may be more effective than aducanumab. Aducanumab, lecanemab and donanemab do not appear to differ in their effectiveness on cognitive function. Low-dose lithium may be safer than aducanumab, lecanemab and donanemab.

Conclusion: Despite the paucity and heterogeneity of studies, LDL's apparent pro-cognitive effects and positive safety profile open promising avenues in the fields of neurodegeneration, and augmentation in affective disorders. We urge future examinations of LDL's potential to prevent cognitive/affective syndromes.

Conclusion: Microdose lithium is associated with better psychiatric and medical outcomes, which are complementary to harms of environmental lead exposure. Experimental animal evidence is supportive, and lead and lithium impact overlapping neurophysiologic pathways. Therefore, several lines of circumstantial evidence suggest that lithium protects against the neurotoxic effects of lead. Further studies are required to clarify the benefits and mechanisms of low-dose lithium. There are significant public health implications if this paper's hypothesis is true.

Conclusion: The evidence supports expanding from transition-focused approaches to broader recovery-oriented frameworks that prioritize psychosis prevention while also addressing functioning, distress, and quality of life in all individuals at risk. We recommend personalized, stage-specific interventions integrating phenomenological, neurobiological, and intervention insights, emphasizing layered assessment, developmentally-contextualized interpretation, trauma-informed care, and accessible neurophysiological markers combined with machine learning for enhanced risk prediction.